人福医药集团股份公司独立董事关于 第十届董事会第五十五次会议相关议案的独立意见 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司独立 董事规则》《上市公司治理准则》《上海证券交易所股票上市规则》和《人福医药 集团股份公司章程》（以下简称"《公司章程》"）的有关规定，作为人福医药 集团股份公司（以下简称"公司"）的独立董事，对公司第十届董事会第五十五次 会议审议的相关议案进行了审查，发表独立意见如下： 一、关于 2023 年半年度募集资金存放与实际使用情况的专项报告 二〇二三年八月二十三日 【以下无正文】 【本页无正文，为人福医药集团股份公司独立董事关于第十届董事会第五十五 次会议相关议案的独立意见之签字盖章页】 独立董事签名：刘林青、周睿、张素华 人福医药集团股份公司董事会 公司严格按照《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》《上海证券交易所股票上市规则》等法律法规的相关规定，规范、合理地使 用募集资金，对募集资金进行了专户存储和专户使用，不存在变相改变募集资金 用途和损害股东利益的情况，不存在违 ...

证券代码：600079 证券简称：人福医药 编号：临 2023-088 号 人福医药集团股份公司 第十届监事会第二十一次会议决议公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）第十届监事会第二 十一次会议于2023年8月23日（星期三）上午9:00在公司会议室以现场结合通讯表决方 式召开，会议通知已于2023年8月13日通过邮件的方式送达各位监事。会议应到监事 五名，参加现场表决的监事三名，监事杜越新、齐民以通讯方式进行表决。 本次监事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定，会议由监事长杜越新先生主持，会议审议并全票通过了以下议案： 议案一、公司2023年半年度报告全文及摘要 公司监事会已审阅公司《2023年半年度报告》及《2023年半年度报告摘要》，认 为公司严格按照股份公司财务制度规范运作，公司2023年半年度报告及其摘要全面、 公允的反映了公司本报告期的财务状况和经营成果。 二〇二三年八月二十五日 表决结 ...

证券代码：600079 证券简称：人福医药 编号：临 2023-089 号 人福医药集团股份公司关于 2023 年半年度募集资金存放与实际使用情况的 专项报告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 经中国证券监督管理委员会证监许可[2020]2562号《关于核准人福医药集团股份 公司向李杰等发行股份购买资产并募集配套资金的批复》核准，公司向李杰、陈小清、 徐华斌发行股份购买相关资产，并于2021年2月向武汉当代科技产业集团股份有限公 司发行89,047,195股人民币普通股募集配套资金，每股面值为人民币1.00元，发行价格 11.23元/股，募集配套资金为人民币999,999,999.85元，扣除各项发行费用22,794,247.01 元，实际募集资金净额为977,205,752.84元。上述资金到位情况已经大信会计师事务所 （特殊普通合伙）验证，并出具大信验字[2021]第2-00005号验资报告。 （二）以前年度已使用金 ...

证券代码：600079 证券简称：人福医药 编号：临 2023-087 号 人福医药集团股份公司 第十届董事会第五十五次会议决议公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）第十届董事会第五十五 次会议于2023年8月23日（星期三）上午9:00在公司会议室以现场结合通讯表决方式召 开，会议通知已于2023年8月13日通过邮件的方式送达各位董事。会议应到董事八名， 参加现场表决的董事四名，董事王学海、刘林青、周睿、张素华以通讯方式进行表决。 公司监事和部分高级管理人员列席了会议。 本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定，会议由董事长李杰先生主持，会议审议并通过了以下议案： 议案一、公司 2023 年半年度报告全文及摘要 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《人福 医药集团股份公司 2023 年半年度报告》及《人福医药集团股份公司 2023 年半年度报 告摘要》 ...

证券代码：600079 证券简称：人福医药 编号：临 2023-090 号 人福医药集团股份公司关于 HW060015 胶囊获得药物临床试验批准通知书的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）全资子公司武汉人福创新 药物研发中心有限公司（以下简称"人福创新中心"）近日收到国家药品监督管理局核 准签发的HW060015胶囊的《药物临床试验批准通知书》，现将相关情况公告如下： 一、药品名称：HW060015胶囊 五、申请人：武汉人福创新药物研发中心有限公司 六、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2023 年6月3日受理的HW060015胶囊符合药品注册的有关要求，同意本品单药在晚期实体瘤 患者中开展临床试验。 HW060015 胶囊临床拟用于晚期实体瘤患者。国内目前尚无同类型产品上市。截至 目前该项目累计研发投入约为 4,400 万元人民币。 二、剂型：胶囊 三、申请事项：境内生产药品注册临床试验 四、注册分类：化学药 ...

HW021199 片进入 II 期临床试验研究的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）子公司湖北生物医药 产业技术研究院有限公司（以下简称"研究院有限公司"，公司持有其84.19%的股权）、 武汉人福利康药业有限公司（以下简称"人福利康"，公司及全资子公司持有其70.28% 的股权，根据增资协议的远期回购约定，公司持有其100%权益）的研发项目HW021199 片于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了IIa期临床试 验登记信息，现将相关情况公告如下： 一、IIa期临床试验相关情况 试验登记号：CTR20232439 证券代码：600079 证券简称：人福医药 编号：临 2023-086 号 人福医药集团股份公司关于 试验通俗题目：一项评价HW021199片用于特发性肺纤维化患者有效性和安全性的 IIa期临床试验。 二、HW021199片主要情况介绍 HW021199片适用于特发性肺纤维化的治疗。目前全球范围内尚无同靶 ...

证券代码：600079 证券简称：人福医药 编号：临 2023-083 号 人福医药集团股份公司 第十届董事会第五十四次会议决议公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 人福医药集团股份公司（以下简称"人福医药"或"公司"）第十届董事会第五十 四次会议于2023年8月16日（星期三）上午10:00以通讯表决方式召开，会议通知已于2023 年8月9日通过邮件的方式送达各位董事。会议应到董事八名，实到董事八名。 本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定，会议由董事长李杰先生主持，会议审议并通过了以下议案： 议案一、关于为公司及子公司提供担保的议案 公司 2022 年年度股东大会审议通过了《关于 2023 年度预计为子公司提供担保的议 案》，2023 年第一次临时股东大会审议通过了《关于调整 2023 年度预计担保额度的议 案》，在上述授权范围内，公司董事会同意实施以下担保事项： 1、同意公司控股子公司湖北葛店人福药业有限责任公司（以下简称"葛店人福"）、 ...

关于为控股子公司提供关联担保的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 证券代码：600079 证券简称：人福医药 编号：临 2023-085 号 人福医药集团股份公司董事会 重要内容提示 ● 被担保人名称： ● 在授权范围内，人福医药集团股份公司（以下简称"人福医药"或"公司"）本次实 施的担保金额及已实际为其提供的担保余额（包含尚未使用的额度）： | 担保 | 被担 | 被担保方 最近一期 | | 期 | | 担保金额 | 已实际为 其提供的 | 股东大会授 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 授信银行 | | 备注 | | | 权担保额度 | | 方 | 保方 | 资产负债 | | 限 | | (万元) | 担保余额 | (万元) | | | | 率 | 中国光大银行股 | | | | （万元） | | | 人福 | 葛店 | | 份有限公司武汉 分行 中国银行股份有 | 1 年 1 年 | 新增 ...

证券代码：600079 证券简称：人福医药 编号：临 2023-084 号 人福医药集团股份公司董事会 关于为公司及子公司提供担保的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 6、北京巴瑞医疗器械有限公司（以下简称"北京医疗"）； 7、湖北人福诺生药业有限责任公司（以下简称"人福诺生"）； 8、人福医药天门有限公司（以下简称"人福天门"）。 重要内容提示 ●被担保人名称： 1、人福医药集团股份公司（以下简称"人福医药"或"公司"）； 2、宜昌人福药业有限责任公司（以下简称"宜昌人福"）； 3、人福普克药业（武汉）有限公司（以下简称"武汉普克"）； 4、武汉人福药业有限责任公司（以下简称"武汉人福"）； 5、新疆维吾尔药业有限责任公司（以下简称"新疆维药"）； ●在授权范围内，本次实施的担保金额及已实际为其提供的担保余额（包含尚未使用的额 度）： | 担保 | 被担 | 被担保方最 | | | | 担保金额 | 已实际为其 | 股东大会授 | | --- | --- | --- | --- | --- ...

Corporate Governance and Compliance - The board of directors proposed a cash dividend of 1.60 RMB per 10 shares (including tax) to all shareholders, pending approval at the 2022 annual general meeting[4]. - The company reported a standard unqualified audit opinion from Da Xin Certified Public Accountants[3]. - The company confirmed the existence of non-operating fund occupation by controlling shareholders and other related parties[5]. - The company has not violated decision-making procedures for external guarantees[5]. - The company emphasizes timely and accurate information disclosure, adhering to relevant regulations to protect investor rights[147]. - The company has a governance structure in place with a supervisory board consisting of 5 members, including 2 employee representatives, ensuring compliance with legal requirements[146]. - The company has actively engaged in investor relations management, providing multiple communication channels to address investor inquiries[148]. - The company has conducted internal training on regulatory changes to enhance compliance awareness among its board and management[150]. - The company has not experienced any insider trading incidents related to sensitive information disclosure during the reporting period[148]. - The company has strengthened its internal control systems, revising the internal control manual and financial management systems to prevent fund occupation[150]. - The company has not faced any penalties from securities regulatory agencies in the past three years, indicating compliance with regulations[161]. - The company confirmed that there were no dissenting opinions from the board regarding the financial reports and operational plans presented[172]. - The company is focused on maintaining the integrity of its financial reporting and ensuring the independence of its auditors[168]. - The board has not identified any risks during the reporting period, indicating a stable operational environment[172]. Financial Performance - The company's operating revenue for 2022 was approximately ¥22.34 billion, representing an increase of 8.71% compared to ¥20.55 billion in 2021[17]. - Net profit attributable to shareholders reached approximately ¥2.48 billion, an increase of 88.60% from ¥1.32 billion in the previous year[17]. - The net profit after deducting non-recurring gains and losses was approximately ¥1.55 billion, up 53.92% from ¥1.01 billion in 2021[17]. - The company's cash flow from operating activities was approximately ¥2.44 billion, reflecting a 12.04% increase from ¥2.18 billion in 2021[17]. - The total assets at the end of 2022 were approximately ¥36.02 billion, a slight increase of 1.74% from ¥35.41 billion at the end of 2021[17]. - The net assets attributable to shareholders increased to approximately ¥15.04 billion, marking a growth of 16.13% from ¥12.95 billion in 2021[17]. - Basic earnings per share for 2022 were ¥1.54, an increase of 85.54% compared to ¥0.83 in 2021[18]. - The weighted average return on equity rose to 17.63%, an increase of 6.73 percentage points from 10.90% in 2021[18]. - The company reported a net profit of approximately ¥259 million in Q4 2022, down from ¥721 million in Q3 2022[19]. - Non-recurring gains and losses totaled approximately ¥936 million in 2022, significantly higher than ¥311 million in 2021[20]. - The company achieved operating revenue of 22.338 billion yuan, an increase of 8.71% compared to the same period last year[26]. - The net profit attributable to shareholders reached 2.484 billion yuan, a significant increase of 88.60% year-on-year[26]. - The net profit excluding non-recurring gains and losses was 1.548 billion yuan, up 53.92% from the previous year[26]. - The company reduced interest-bearing liabilities by approximately 2.7 billion yuan, resulting in a decrease of interest expenses by 126 million yuan year-on-year[26]. - The asset-liability ratio improved from 55.79% at the beginning of the period to 50.19% at the end of the period[29]. - The company sold various equity stakes and recovered investment funds of approximately 3.9 billion yuan, achieving an investment income of about 800 million yuan[29]. - The company reported a foreign exchange gain of approximately 182 million yuan due to currency fluctuations[26]. Research and Development - The company is focusing on the development of innovative drugs and specialty generic drugs, enhancing its product competitiveness through increased R&D investment[37]. - The company has established R&D centers in Wuhan, Yichang, New Jersey, and St. Louis, employing 1,758 pharmaceutical R&D personnel, including 196 PhDs and 7 experts receiving special government allowances[91]. - The company’s R&D expenditure for 2022 was CNY 113,397.67 million, an increase of 6.92% year-on-year, representing 5.08% of the current operating revenue[100]. - The R&D investment capitalized ratio for the company was 14.74% in the reporting period, compared to an industry average of 4.19% for comparable companies[100]. - The company is actively pursuing clinical trials for drugs targeting specific conditions, such as ADHD and postoperative pain management[96]. - The company is committed to enhancing its research capabilities and ensuring compliance with regulatory standards in drug development[98]. - The company is focusing on developing seven core product lines and nurturing new growth points within established segments[129]. - The company plans to continue its cash dividend policy while also supporting funding needs for R&D, engineering projects, and business expansion[181]. Market Expansion and Strategy - The company is actively exploring international markets, with subsidiaries in Africa working on product registration despite local challenges[29]. - The company aims to expand its market presence in mature markets such as Europe and the United States, as well as emerging markets in Africa, Central Asia, and Southeast Asia[42]. - The company is committed to international expansion, leveraging existing overseas subsidiaries to enhance product and market reach[130]. - The company plans to achieve revenue of over 24 billion yuan in 2023, with a comprehensive gross margin of over 43%[131]. - The company will maintain an annual R&D investment of around 10% of pharmaceutical industrial revenue during the 14th Five-Year Plan period[129]. - The company aims to enhance market access by striving for more products, especially exclusive varieties, to enter the basic medical insurance drug catalog and actively seek qualification for centralized drug procurement and reasonable pricing[136]. - The company is pursuing market expansion through new product approvals and ongoing clinical trials for innovative therapies[94]. Environmental Responsibility - The company invested 68.662 million yuan in environmental protection during the reporting period[193]. - The total discharge of COD was 383.586 tons, with a concentration range of 80.5-287.942 mg/L, complying with the standard of 400 mg/L[193]. - The company has established environmental protection mechanisms and emphasizes compliance with national environmental laws and regulations[193]. - The company is committed to green development and continuous improvement in environmental management practices[193]. - The company has implemented effective monitoring and management of wastewater, waste gas, and hazardous waste[193]. - The company’s environmental facilities are operating normally, ensuring compliance with environmental requirements[193]. Employee Management and Compensation - The company has established a multi-faceted training program to enhance employee skills, including new employee training, professional skills training, and leadership training[176]. - The company has implemented a performance-linked floating salary mechanism as part of its compensation policy to motivate employees and ensure sustainable development[175]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 14.2746 million yuan[160]. - The company established a performance evaluation system for senior management, linking compensation and performance rewards to the achievement of business goals[187]. - The total number of employees in the parent company and major subsidiaries is 16,070, with 483 in the parent company and 15,587 in subsidiaries[173]. Risk Management - The company faces operational risks due to potential changes in tax policies affecting its subsidiaries' tax benefits, which could impact overall performance[137]. - The company is exposed to safety and environmental risks due to increased regulatory scrutiny and rising safety and environmental costs[140]. - The company is committed to strategic management and enhancing operational management levels to mitigate risks associated with its numerous subsidiaries and international operations[143].